TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02192879

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural
Description: Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous paravertebral catheter
Description: Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Controlled Analgesia
Description: Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
Study: NCT01028937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimal Keratoplasty
Description: Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
Study: NCT02868385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4x Praziquantel
Description: Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1x Praziquantel
Description: One praziquantel treatment (40 mg/kg) at baseline
Study: NCT00160043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH T00268C
Description: 1250 mg experimental drug od

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ ZK 222584
Description: 1250 mg experimental drug bid (500mg + 750mg)
Study: NCT00038168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine
Description: Intravenous dose
Study: NCT02141295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Vanucizumab will be administered according to dose and schedule described in respective arm.
Study: NCT00038168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Intravenous dose
Study: NCT00372229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir CMV Prophylaxis
Description: 900 mg valganciclovir, taken orally once daily, adjusted to renal function starting within 14 days of transplantation until Day 100 after transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir (Pre-emptive CMV Therapy)
Description: If plasma polymerase chain reaction (PCR) ≥ 400 CMV copies/millilitre, then 1800 mg valganciclovir per day adjusted to renal function for at least 14 days until the second negative PCR (below 400 copies/ml) followed by secondary prophylaxis for 28 days with 900 mg valganciclovir adjusted to renal function. If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: If CMV disease or no response to valganciclovir treatment after 14 days (not falling viral load), then intravenous (IV) ganciclovir or additional appropriate therapy could have been administered according to the local site's standard, instead of valganciclovir.
Study: NCT02719587

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo drug identical except for the fish oil supplement, were only performed at baseline.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: omega-3 PUFAs supplement, were only performed at baseline.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP
Description: Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
Study: NCT02797574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy at a Lesional Site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy at a Non- Lesional site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy at a Non- Lesional site
Study: NCT02619487

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: text message to parent only
Description: A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: text message to parent only
Description: A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: text message to parent and adolescent
Description: A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
Study: NCT01179425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stressor
Description: The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive stressor
Description: The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
Study: NCT04059419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARQVE Program
Description: Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
Study: NCT02141295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Vanucizumab will be administered according to dose and schedule described in respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Vanucizumab will be administered according to dose and schedule described in respective arm.
Study: NCT03629535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive non-oscillometric blood pressure wristband device
Description: The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive intra-arterial blood pressure monitors.
Description: Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
Study: NCT00998686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 100 mg
Study: NCT01245530

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept Comparator Intervention: Drug: Aricept 5\~10 mg orally every day for 24weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INM-176
Description: INM-176: Experimental Intervention: Drug:INM-176 600\~1200 mg orally every day for 24weeks
Study: NCT01389596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin add-on therapy
Description: Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin add-on therapy
Description: Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin add-on therapy
Description: Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
Study: NCT04059419

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Care
Description: Remain under geriatric care as usual
Study: NCT03568331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT03008707

Intervention type: PROCEDURE
Intervention: Laparoscopic Peritoneal Lavage
Description: LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
Study: NCT03412305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consisting of 4 tablets, orally 1 hour before implant placement
Study: NCT01680068

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy and postoperative air tamponade
Description: Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
Study: NCT00495586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill to be taken every eight hours for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin and clavulanic acid
Description: 500-125 mg to be taken every eight hours for 8 days
Study: NCT04049799

Intervention type: OTHER
Intervention: Medically-supervised withdrawal
Description: 6-8 day withdrawal with buprenorphine/naloxone

Intervention type: OTHER
Intervention: Opioid agonist treatment
Description: Induction and maintenance with buprenorphine/naloxone

Intervention type: BEHAVIORAL
Intervention: Comprehensive clinical care
Description: Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening

Intervention type: BEHAVIORAL
Intervention: Comprehensive clinical care
Description: Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
Study: NCT04267302

Intervention type: OTHER
Group type: OTHER
Intervention: Baby Bouncer
Description: Fischer Price baby bouncer.

Intervention type: OTHER
Group type: OTHER
Intervention: Baby Bouncer
Description: Fischer Price baby bouncer.

Intervention type: OTHER
Group type: OTHER
Intervention: Infant t-shirts with Language Environment Analysis (LENA) audio recorders
Description: Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.

Intervention type: OTHER
Group type: OTHER
Intervention: Infant t-shirts with Language Environment Analysis (LENA) audio recorders
Description: Infant t-shirts with wearable LENA audio recorders for 2-8 hours of recordings of vocal interaction, crying and turn-taking.

Intervention type: OTHER
Group type: OTHER
Intervention: Baby Carrier
Description: Ergobaby Baby carrier.

Intervention type: OTHER
Group type: OTHER
Intervention: Baby Carrier
Description: Ergobaby Baby carrier.
Study: NCT00116337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation to restore cough
Description: Participants will have small electrodes (metal discs) placed - by a routine surgical procedure - over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Stimulator
Description: The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
Study: NCT03486847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive recruitment with PEEP
Description: Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One recruitment with PEEP
Description: Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
Study: NCT02206594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemetorhexis
Study: NCT03287531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: Exercise therapeutic Ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
Study: NCT03765099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interactions
Description: Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-Assisted Interactions
Description: Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
Study: NCT02440009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral itraconazole 200 mg BD for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
Study: NCT00913315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine
Description: 4 mg of tolterodine ER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin
Description: 0.4 mg of tamsulosin once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: 0.4 mg of tamsulosin once a day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo once a day for 8 weeks
Study: NCT02274818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexible Duty Hour Schedule
Description: IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~* No more than 80 hours of work per week (when averaged over 4 weeks)~* 1 day off in 7 (when averaged over 4 weeks)~* In-house call no more frequently than every 3rd night (when averaged over 4 weeks)
Study: NCT04256577

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ceramides level in blood
Description: Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ceramides level in blood
Description: Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)

Intervention type: DIAGNOSTIC_TEST
Intervention: serum ceramides level in blood
Description: Serum ceramides ( sphingolipid measurement, plasma (EDTA as anticoagulant) and serum separation was performed immediately after blood drawing by two-time scentrifugation at 750 x g for 5 min (4°C). Lipid extraction from plasma and/or serum samples (10 µl each) and subsequent LC-MS/MS)
Study: NCT00833131

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course of radiotherapy
Description: 5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: 28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
Study: NCT04315051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1 J. Lividum
Description: Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Subject to apply Placebo Gel daily on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails.
Study: NCT03105622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV and music
Description: Watching TV or listening to music while running on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV and music
Description: Watching TV or listening to music while running on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV and music
Description: Watching TV or listening to music while running on a treadmill
Study: NCT04168853

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vascular reactivity of internal thoracic arteries
Description: 1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vascular reactivity of internal thoracic arteries
Description: 1. Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~2. Blood sampling and biochemical analysis
Study: NCT00647725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active phrase epidural analgesia
Description: Continuous epidural analgesia with sufentanil plus ropivacaine
Study: NCT05277415

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: Ghrelin infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04289935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum assisted biopsy (VAB)
Description: The trial intervention consists of a diagnostic interventional procedure, US-guided or mammographically guided VAB post-NAC, prior to the standard breast surgery.
Study: NCT00647725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latent phrase epidural analgesia
Description: Continuous epidural analgesia with sufentanil plus ropivacaine
Study: NCT03297931

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn Chips + Onion Dip
Description: Non-pulse chip + non-pulse dip

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yellow pea chip + hummus
Description: Novel pulse chip + pulse spread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinto bean chip + hummus
Description: Commercial pulse chip + pulse spread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pinto bean chip + onion dip
Description: Commercial pulse chip + non-pulse spread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yellow pea chip + onion dip
Description: Novel pulse chip + non-pulse spread

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn chips + hummus
Description: Non-pulse chip + pulse spread